AMETEK

AME · NYSE

$247.36+$0.14 (+0.06%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $247.22

AME analyst rating

BuyConsensus of 14 analysts over the last 12 months. 57% rate it a buy.

Strong buy0
Buy8
Hold6
Underperform0
Sell0

12-month price target · 20 analysts

Average $285.90 (+15.6% upside)

Low: $219.19
Now: $247.36
High: $333.90

Upgrades and downgrades

The latest rating actions, newest first

AME analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Oct 12, 2026	Maintains	Neutral	$261.00 → $263.00	63%
Baird	Oct 5, 2026	Maintains	Neutral	$275.00 → $280.00	67%
BNP Paribas	Sep 11, 2026	Maintains	Outperform	$280.00 → $290.00	58%
Truist Securities	Aug 6, 2026	Maintains	Buy	$303.00 → $316.00	59%
TD Cowen	Aug 6, 2026	Maintains	Buy	$260.00 → $275.00	59%
DA Davidson	Aug 5, 2026	Maintains	Buy	$265.00 → $285.00	49%
Citigroup	Aug 5, 2026	Maintains	Neutral	$257.00 → $261.00	63%
BNP Paribas	Aug 5, 2026	Maintains	Outperform	$270.00 → $280.00	58%
RBC Capital	Aug 5, 2026	Maintains	Outperform	$260.00 → $291.00	57%
Keybanc	Aug 5, 2026	Maintains	Overweight	$260.00 → $295.00	61%

The case for and against

Updated Oct 14, 2026

Bull case

AMETEK is supported by a differentiated niche-market portfolio, with more than 40 autonomous businesses serving resilient end markets such as medical, aerospace and defense, power, automation, and manufacturing, which helps sustain pricing power and above-average growth. The latest quarter showed that strength is broadening, as 1Q26 sales rose 11% to $1.928B, adjusted EPS increased 13% to $1.97, organic orders jumped 22% to a record $2.2B, and backlog reached about $3.87B, equal to roughly 45% of FTM sales. Its outlook is further reinforced by a very strong balance sheet with net leverage of 0.7x, 107% FCF conversion in 1Q26, and an active M&A pipeline that supports continued capital compounding and earnings growth.

Bear case

AMETEK is vulnerable to a weaker outlook because its exposure to cyclical markets such as oil & gas, industrial, process, aerospace, and military can quickly translate a slower economic recovery or recession into softer revenue and operating income. Its roughly 19% revenue exposure to Europe and about 50% of sales outside the US add meaningful macro and currency risk, while tighter capex budgets, trade-related headwinds, and a stronger USD could pressure demand, pricing, and realization. The company’s reliance on acquisitions also creates integration and overpayment risk, and any slowdown in its highly profitable aerospace or industrial end markets could amplify margin pressure.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.